Evidence map›Paper›PMID 27837218›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2017

Detailed molecular characterization of a novel IDS exonic mutation associated with multiple pseudoexon activation.

L Grodecká, T Kováčová, M Kramárek, S Seneca, K Stouffs, C De Laet, F Majer, T Kršjaková, P Hujová, K Hrnčířová and 4 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

L GrodeckáCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
T KováčováCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
M KramárekCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
S SenecaCenter for Medical Genetics, UZ Brussel and Vrije Universiteit Brussel, 1090, Brussels, Belgium.
K StouffsCenter for Medical Genetics, UZ Brussel and Vrije Universiteit Brussel, 1090, Brussels, Belgium.
C De LaetNutrition and Metabolism Unit, University Children's Hospital Queen Fabiola, Free University of Brussels (ULB), 1020, Brussels, Belgium.
F MajerInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic.
T KršjakováCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
P HujováMolecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation, Pekařská 53, 656 91, Brno, Czech Republic.
K HrnčířováCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
P SoučekCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
W LissensCenter for Medical Genetics, UZ Brussel and Vrije Universiteit Brussel, 1090, Brussels, Belgium.
E BurattiInternational Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
Tomas FreibergerCentral European Institute of Technology, Masaryk University, Brno, Czech Republic. tomas.freiberger@cktch.cz.ORCID 0000-0001-6532-7053
Central European Institute of Technology · CZVrije Universiteit Brussel · BECentrum kardiovaskulární a transplantační chirurgie · CZCharles University · CZInternational Centre for Genetic Engineering and Biotechnology · ITQueen Fabiola Children's University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations affecting splicing underlie the development of many human genetic diseases, but rather rarely through mechanisms of pseudoexon activation. Here, we describe a novel c.1092T>A mutation in the iduronate-2-sulfatase (IDS) gene detected in a patient with significantly decreased IDS activity and a clinical diagnosis of mild mucopolysaccharidosis II form. The mutation created an exonic de novo acceptor splice site and resulted in a complex splicing pattern with multiple pseudoexon activation in the patient's fibroblasts. Using an extensive series of minigene splicing experiments, we showed that the competition itself between the de novo and authentic splice site led to the bypass of the authentic one. This event then resulted in activation of several cryptic acceptor and donor sites in the upstream intron. As this was an unexpected and previously unreported mechanism of aberrant pseudoexon inclusion, we systematically analysed and disproved that the patient's mutation induced any relevant change in surrounding splicing regulatory elements. Interestingly, all pseudoexons included in the mature transcripts overlapped with the IDS alternative terminal exon 7b suggesting that this sequence represents a key element in the IDS pre-mRNA architecture. These findings extend the spectrum of mechanisms enabling pseudoexon activation and underscore the complexity of mutation-induced splicing aberrations. KEY MESSAGE: Novel exonic IDS gene mutation leads to a complex splicing pattern. Mutation activates multiple pseudoexons through a previously unreported mechanism. Multiple cryptic splice site (ss) activation results from a bypass of authentic ss. Authentic ss bypass is due to a competition between de novo and authentic ss.

Indexed as

AdolescentExonsGlycoproteinsHumansIntronsMaleMucopolysaccharidosis IIMutationPoint MutationRNA, MessengerRNA Splice SitesRNA SplicingGlycoproteinsIDS protein, humanRNA, MessengerRNA Splice SitesComplex splicing aberrationDe novo splice siteIDSPseudoexonSplice site competition

Identifiers

PMID27837218
OpenAlexW2557226781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.